Andreas Wildi

Andreas Wildi

Partner

Expertise

  • Healthcare & Life Science
  • Regulatory
  • Healthcare & Life Sciences

WSG Practice Industries

Activity

Walder Wyss Ltd.
Switzerland

WSG Leadership

Healthcare & Life Sciences
Co-Chair
Regulatory
Co-Chair
Life Sciences Group
Member
Profile
Andreas Wildi, born in 1972, is a medical doctor and an attorney at law. He consults and represents Dow Jones and Nasdaq listed multinational companies as well as mid- and small cap enterprises in the Life Sciences sector. He mainly focuses on Swiss and international reimbursement & pricing law of pharmaceuticals and other therapeutic products. Regulatory issues of pharmaceuticals, medical devices, special nutrition, cosmetics, genetic testing, stem cell- and blood products are his further key areas of practise.

Andreas Wildi studied medicine at the University of Zurich and graduated as medical doctor (MD). Working part-time in hospital, GP-practice and on international rescue missions, he completed his law degree at the University of St. Gallen HSG (MLaw). Before passing the bar exam, he gained his first professional legal experience as clerk with the Cantonal Court of Schaffhausen and with a recognised business law firm in Zurich. From his first position as an attorney at law in a large Zurich business law firm, Andreas Wildi was asked to work for the Swiss Government, where he led the pharmaceutical reimbursement & pricing unit in the Federal Office of Public Health. Thereafter, Andreas Wildi broadened his market access expertise internationally, as EMEA market access law director for Janssen Pharmaceuticals (Johnson & Johnson). Since 2012, he has built up his legal practise in a large, well accepted Zurich business law firm. In 2015, Walder Wyss elected Andreas Wildi as their partner.

Andreas Wildi works in German, French and English. He is admitted to all Swiss Courts and guest lecturer on pharmaceutical law at the University of Lucerne’s Faculty of Law.
Areas of Practice

Healthcare & Life Science | Healthcare & Life Sciences | Regulatory

Professional Career

Significant Accomplishments


Dr. Wild & Co. AG verkauft ihr Pharmageschäfts an die Verfora AG

Neues Handbuch: Lebensmittel- und Gebrauchsgegenständerecht

Walder Wyss erhält die Who’s Who Legal Auszeichnungen Swiss Law Firm of the Year 2019 in den Bereichen «Data» und «Life Sciences»

Verdict of Swiss Federal Administrative Court C-595/2015, BAG-therapeutic-cross-comparison revoked

IPO Medartis an SIX Swiss Exchange

Metall Zug (SIX: METN) übernimmt Mehrheit an der Haag-Streit Holding AG

Neuer Partner bei Walder Wyss


Articles

Impact of Medical Device Regualtions (MDR) Postponement on Swiss Medtech Industry
, June 2020

  MDR postponement On 17 April 2020 the European Parliament decided to postpone the transition timeline to implement the EU Medical Device Regulation (MDR), which was set to expire on 26 May 2020, until 26 May 2021. The EU MDR postponement was published in the Official Journal of the European Union and entered into force on 24 April 2020...

Impact of Medical Device Regualtions (MDR) Postponement on Swiss Medtech Industry
Walder Wyss Ltd., June 2020

  MDR postponement On 17 April 2020 the European Parliament decided to postpone the transition timeline to implement the EU Medical Device Regulation (MDR), which was set to expire on 26 May 2020, until 26 May 2021. The EU MDR postponement was published in the Official Journal of the European Union and entered into force on 24 April 2020...

Court Annuls FOPH Order Limiting Medicinal Product Price Increase
, December 2019

On 7 August 2019 the Federal Administrative Court annulled a Federal Office of Public Health (FOPH) order that had limited the price increase of a medicinal product on the list of specialities to two years. The product manufacturer had requested a price increase under Article 67(2) of the Healthcare Insurance Ordinance (SR 832.102), having incurred higher costs following the loss of two suppliers...

Additional Articles


Inkrafttreten der geänderten Schweizer Medizinprodukteverordnung und deren Auswirkungen für die Medizintechnikindustrie
Das Life Sciences Law Review, Kapitel 24 – Schweiz
Pharmawerbung – Schweiz
Liberté de choix de la thérapie vs principe du caractère économique dans le domaine de la liste des spécialités
Therapiewahlfreiheit vs. Wirtschaftlichkeitsgebot im Bereich der Spezialitätenliste
Kapitel 16: Schweiz
Chapter 16: Switzerland
Update: Postponement of EU Medical Device Regulation implementation due to COVID-19
The Life Sciences Law Review Chapter 28 - Switzerland
Postponement of EU Medical Device Regulation implementation due to COVID-19
Die Abgrenzung von Lebensmitteln und Heilmitteln
Art. 40, 52, 52a KVG
Life Science Law Update
Life Science Law Update
Life Science Law Update
Life Science Law Update
Life Science Law Update
The Life Sciences Law Review - Chapter 29: Switzerland
Pharmawerbung – Schweiz
Arzneimittel sind kein knappes Gut
Limitierung von Arzneimitteln im Krankenversicherungsrecht: Wo wird die Grenze zur Rationierung überschritten?
Schränken hohe Arzneimittelpreise die ärztliche Therapiefreiheit ein?
Vertragshandbuch Pharma und Life Sciences – Besonderheiten des Schweizer Rechts, 10. Kapitel
Ärztliche Freiheit trotz Kontraindikationen?
Nebenwirkungen des Bundesratsenscheids, Kommentar in der NZZ zu Änderungen der Schweizer Arzneimittelpreisfestsetzung
Eine Wegleitung für die medizinische und pharmazeutische Praxis sowie für Behörden und Versicherer